These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 20065190)
1. Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials. Rose SL; Krzyzanowska MK; Joffe S J Clin Oncol; 2010 Mar; 28(8):1316-21. PubMed ID: 20065190 [TBL] [Abstract][Full Text] [Related]
2. Authorship and industry financial relationships: the tie that binds. Johnson DH; Horn L J Clin Oncol; 2010 Mar; 28(8):1281-3. PubMed ID: 20065171 [No Abstract] [Full Text] [Related]
3. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. Bariani GM; de Celis Ferrari AC; Hoff PM; Krzyzanowska MK; Riechelmann RP J Clin Oncol; 2013 Jun; 31(18):2289-95. PubMed ID: 23630201 [TBL] [Abstract][Full Text] [Related]
4. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. Turner K; Carboni-Jiménez A; Benea C; Elder K; Levis B; Boruff J; Roseman M; Bero L; Lexchin J; Turner EH; Benedetti A; Thombs BD BMJ Open; 2020 May; 10(5):e035633. PubMed ID: 32398334 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan. Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027 [TBL] [Abstract][Full Text] [Related]
6. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. Riechelmann RP; Wang L; O'Carroll A; Krzyzanowska MK J Clin Oncol; 2007 Oct; 25(29):4642-7. PubMed ID: 17925561 [TBL] [Abstract][Full Text] [Related]
7. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079 [TBL] [Abstract][Full Text] [Related]
8. Industry Collaboration and Primary Guest Authorship of High-Impact Randomized Clinical Trials: A Cross-Sectional Study. Roper N; Korenstein D J Gen Intern Med; 2015 Oct; 30(10):1421-5. PubMed ID: 25832619 [TBL] [Abstract][Full Text] [Related]
9. Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines Authors. Checketts JX; Sims MT; Vassar M JAMA Dermatol; 2017 Dec; 153(12):1229-1235. PubMed ID: 29049553 [TBL] [Abstract][Full Text] [Related]
10. Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications. Marušić A; Hren D; Mansi B; Lineberry N; Bhattacharya A; Garrity M; Clark J; Gesell T; Glasser S; Gonzalez J; Hustad C; Lannon MM; Mooney LA; Peña T BMC Med; 2014 Oct; 12():197. PubMed ID: 25604352 [TBL] [Abstract][Full Text] [Related]
11. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Perlis RH; Perlis CS; Wu Y; Hwang C; Joseph M; Nierenberg AA Am J Psychiatry; 2005 Oct; 162(10):1957-60. PubMed ID: 16199844 [TBL] [Abstract][Full Text] [Related]
12. Industry compensation and self-reported financial conflicts of interest among authors of highly cited peripheral artery disease studies. Bellomo TR; Hwang C; Spector-Bagdady K; Stanley JC; Corriere MA J Vasc Surg; 2020 Aug; 72(2):673-684. PubMed ID: 31980241 [TBL] [Abstract][Full Text] [Related]
13. Biased articles. Friedman JH Med Health R I; 2009 Mar; 92(3):70. PubMed ID: 19385378 [No Abstract] [Full Text] [Related]
14. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. Moynihan R; Lai A; Jarvis H; Duggan G; Goodrick S; Beller E; Bero L BMJ Open; 2019 Feb; 9(2):e025864. PubMed ID: 30813119 [TBL] [Abstract][Full Text] [Related]
15. Authors of clinical trials reported individual and financial conflicts of interest more frequently than institutional and nonfinancial ones: a methodological survey. Hakoum MB; Jouni N; Abou-Jaoude EA; Hasbani DJ; Abou-Jaoude EA; Lopes LC; Khaldieh M; Hammoud MZ; Al-Gibbawi M; Anouti S; Guyatt G; Akl EA J Clin Epidemiol; 2017 Jul; 87():78-86. PubMed ID: 28412465 [TBL] [Abstract][Full Text] [Related]
16. Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Cosgrove L; Bursztajn HJ; Krimsky S; Anaya M; Walker J Psychother Psychosom; 2009; 78(4):228-32. PubMed ID: 19401623 [TBL] [Abstract][Full Text] [Related]
17. Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan. Saito H; Tani Y; Ozaki A; Sawano T; Shimada Y; Yamamoto K; Tanimoto T Clin Microbiol Infect; 2019 Nov; 25(11):1304-1306. PubMed ID: 31401175 [No Abstract] [Full Text] [Related]
18. Financial disclosures of scientific papers presented at the 2003 RSNA Annual Meeting: association with reporting of non-Food and Drug Administration-approved uses of industry products. Brown SD; Daly JC; Kalish LA; McDaniel SA Radiology; 2006 Jun; 239(3):849-55. PubMed ID: 16641343 [TBL] [Abstract][Full Text] [Related]
19. Reliability of disclosure forms of authors' contributions. Ilakovac V; Fister K; Marusic M; Marusic A CMAJ; 2007 Jan; 176(1):41-6. PubMed ID: 17200389 [TBL] [Abstract][Full Text] [Related]
20. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Choudhry NK; Stelfox HT; Detsky AS JAMA; 2002 Feb; 287(5):612-7. PubMed ID: 11829700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]